Diagens Biotechnology Nears IPO After Passing HKSE Listing Hearing

Why It Matters

Commercializing a validated AI foundation model could dramatically speed diagnostics and expand AI‑enabled care in China’s fast‑growing chromosome analysis market, setting a precedent for AI‑centric biotech IPOs.

Key Takeaways

• AI Autovision hit 100% sensitivity for numerical abnormalities
• iMedImage supports 19 imaging modalities, covering 90% scenarios
• Revenue rose to RMB 112 million, up 460% YoY
• Holds 30.6% market share in Chinese karyotype analysis
• IPO funds will boost AI model development and global expansion

Pulse Analysis

The rise of foundation models in healthcare mirrors the broader AI revolution sparked by large language models. In medical imaging, a single, general‑purpose model can be fine‑tuned for modalities such as ultrasound, CT, and microscopy, delivering consistent performance across diverse datasets. This cross‑domain ability shortens development cycles, cuts costs, and eases regulatory approval for hospitals adopting advanced diagnostics. As global regulators draft guidelines for AI‑assisted tools, firms with validated, scalable models gain a decisive competitive edge. These models also enable continuous learning from new scans, improving diagnostic accuracy over time.

Diagens has turned its iMedImage foundation model into AI Autovision, a full‑workflow chromosome‑karyotyping solution that automates cell harvesting, slide preparation, imaging, and interpretation. In a 1,518‑sample multicenter trial, the system achieved 100% sensitivity and specificity for numerical abnormalities and 94% sensitivity for structural defects, while reducing analysis time by more than threefold. The company now holds a 30.6% share of China’s karyotype market and posted RMB 112 million revenue in Q3 2025—a 460% year‑over‑year increase—demonstrating the commercial promise of AI‑enhanced cytogenetics. The platform’s cloud‑based analytics also facilitate data sharing across research institutions, fostering collaborative studies.

The pending Hong Kong IPO makes Diagens the first listed AI‑driven medical imaging firm, signaling strong investor belief in the sector’s growth. Funds will expand iMedImage’s modality coverage, boost cloud processing capacity, and support licensing for remote hospitals lacking specialist expertise. China’s 2023 AI‑in‑healthcare policy aims to deploy AI diagnostics in secondary‑level hospitals by 2030, creating a sizable addressable market. Successful scaling could accelerate Diagens’ global reach and provide a template for biotech companies monetizing foundation‑model AI. Strategic partnerships with multinational device manufacturers could further embed iMedImage into existing imaging hardware, expanding its ecosystem.

Deal Summary

Diagens Biotechnology, a Hangzhou‑based AI‑driven medical imaging firm, passed its Hong Kong Stock Exchange listing hearing and released its post‑hearing prospectus on March 15, 2026, positioning it to become the world’s first publicly listed company offering AI‑based imaging tools. The company plans to use IPO proceeds for R&D of its AI Autovision platform, expansion of the iMedImage foundation model, and global market growth.